BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Report Library

All Reports
Datamonitor Healthcare Oncology Disease Analysis: Renal Cell Carcinoma (RCC)

June 29, 2022

The majority (75%) of renal cell carcinoma (RCC) cases have a clear cell histology (ccRCC), to which most first-line treatment regimens are specialized. The next most common histology is papillary RCC, comprising 15% of RCCs. 

Nearly all pharmacological interventions are administered in metastatic RCC. Sutent or Keytruda may be prescribed as a postoperative adjuvant therapy in locoregional disease, but the typical approach is nephrectomy alone. Welireg is another therapy recently approved for advanced disease, but is limited to treating patients with germline loss of function mutations in the tumor suppressor gene von Hippel-Lindau (VHL)

This Datamonitor Healthcare report contains a Disease Analysis module.

Indications Covered: Renal Cell Cancer (RCC)
Back to the top Back to the top